2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Vaccines, Bispecific Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Measurable Residual Disease, ALL, B Cell Lymphoma, T Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5052 Thrombosis following calaspargase pegol versus pegaspargase in pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma: A propensity score–matched cohort study

Mary P Dang, MD, Wyatt D'Spain, MD2, Caroline Smith, MD3, William G. Mitchell, MD, MS4, Hana Hendi5, Ying Lee, PharmD6, Kyra McCarty, DO7, Hu Chen, MS8, Jialiang Liu, PhD, MPH9, Ayesha N Zia, MD, MSCS10
1 University of Texas Southwestern Medical School, Dallas, Texas, United States
2 University of Texas Southwestern Medical School, Dallas, Texas, United States
3 University of Texas Southwestern Medical School, Dallas, Texas, United States
4 University of Texas Southwestern Medical School, Dallas, Texas, United States
5 University of Texas Southwestern Medical School, Dallas, Texas, United States
6 University of Texas Southwestern Medical School, Dallas, Texas, United States
7 Duke University Hospital, Durham, North Carolina, United States
8 University of Texas Southwestern Medical School, Dallas, Texas, United States
9 University of Texas Southwestern Medical School, Dallas, Texas, United States
10 University of Texas Southwestern Medical School, Dallas, Texas, United States
Background: Calaspargase pegol (Cal-PEG) provides prolonged asparaginase exposure compared with pegaspargase (PEG), potentially extending hemostatic perturbations and increasing thrombosis risk. Whether Cal-PEG increases thrombosis compared with PEG remains uncertain. We compared thrombosis following Cal-PEG versus PEG in children/adolescents and evaluated its impact on subsequent asparaginase delivery and leukemia outcomes.

Methods:
The primary outcome was development of thrombosis following asparaginase exposure. Secondary outcomes included timing relative to asparaginase exposure; interruption or discontinuation of asparaginase; asparaginase rechallenge; and leukemia outcomes including event-free survival and overall survival. The cohort primarily reflected treatment according to contemporary Children's Oncology Group–based protocols. Because treatment allocation differed by treatment era, propensity score matching (PSM) was performed to reduce potential confounding. Patients receiving PEG were matched 2:1 to patients receiving Cal-PEG based on age and leukemia risk group, defined according to immunophenotype and risk status at diagnosis and end of induction. Thrombosis before matching was compared using Fisher's exact test. Following PSM, weighted logistic regression accounting for matching weights was used to compare thrombosis between groups, and absolute risk differences with 95% confidence intervals (CI) were estimated using average marginal effects.

Results:
247 patients were included (PEG 190; Cal-PEG 57). Mean age at diagnosis was similar (8.3 versus 8.7 years; p=0.6), as were immunophenotype, race, CNS status, BMI percentile, WBC at diagnosis, and the prespecified composite risk group. Cal-PEG recipients were more frequently male (82.5% versus 54.7%; p<0.001) and more frequently classified as high risk at diagnosis (64.9% versus 42.1%; p<0.01). Overall, 19/247 (7.7%) had thrombosis. Before matching, thrombosis occurred in 7/57 (12.3%) patients receiving Cal-PEG compared with 12/190 (6.3%) receiving PEG (p=0.158). After PSM (n=171; Cal-PEG 57, PEG 114), thrombosis remained numerically higher with Cal-PEG (12.3% vs 7.0%), with an adjusted absolute risk increase of 5.3 percentage points (95% CI, −3.1 to 13.6; p=0.219).

Most thromboses involved an extremity (14/19, 73.7%); 5 (26.3%) occurred at clinically high-risk sites, including cerebral sinovenous thrombosis and pulmonary embolism. Overall, 9/19 (47.4%) were catheter-associated. Thrombosis occurred most often during induction (10/19, 52.6%), followed by consolidation (7/19, 36.8%), at a median of 27 days (IQR, 20–60) after first asparaginase exposure and 19 days (IQR, 12.5–25) after the most recent dose.

Among patients with thrombosis, 16/19 (84.2%) received anticoagulation. Bleeding occurred in 9/16 anticoagulated patients (56.3%), comprising 13 events: 4 major, 6 clinically relevant non-major, and 3 minor.

Following thrombosis, asparaginase was modified in 3/19 patients (15.8%): one had a dose omitted and two transitioned to recombinant Erwinia asparaginase. No patient discontinued all remaining asparaginase therapy. Among the 15 patients with additional asparaginase planned after thrombosis, modification occurred in 2/7 Cal-PEG (28.6%) versus 1/8 PEG (12.5%) recipients (p=0.569); 10/15 (66.7%) completed all remaining doses without new or progressive thrombosis, whereas 5 (33.3%) developed thrombus at a new site (n=4) or progression of the index thrombus (n=1). 

Patients with thrombosis had inferior 2-year overall survival (76.5% versus 93.7%, p=0.03) and numerically lower event-free survival (64.7% versus 87.4%, p=0.09). Adjusted time-to-event analyses accounting for leukemia risk group and treatment characteristics are ongoing.

Conclusion:
In this retrospective propensity score–matched cohort, Cal-PEG demonstrated a clinically meaningful increase in thrombosis compared with PEG, although the study was not powered to detect modest between-group differences. Thrombosis occurred early during therapy and identified a subgroup of patients with inferior overall survival despite contemporary anticoagulation and frequent successful asparaginase rechallenge, suggesting that thrombosis may represent a marker of adverse disease biology or treatment-related risk rather than treatment interruption alone. These findings identify a clinically important thrombotic safety signal associated with Cal-PEG that warrants validation in larger multicenter studies.
Mary P Dang, MD: No relevant conflicts of interest to declare.